data + articles · 3 listed
newest 2020spec sheet10 rows
3-MeO-PCMo (4-[1-(3-methoxyphenyl)cyclohexyl]morpholine) is a morpholine-ring arylcyclohexylamine related to 3-MeO-PCP and the wider phencyclidine family. In receptor screening it shows moderate affinity for the NMDA receptor comparable to that of ketamine and roughly twelve-fold lower than PCP, supporting anecdotal reports of dissociative effects in humans. Preclinical work indicates rewarding and reinforcing properties mediated through the mesolimbic dopamine system, with accompanying changes in accumbal signaling proteins and cortical electroencephalographic activity, suggesting abuse potential. It is a very obscure substance with minimal human data, so its safety profile remains poorly defined.
- Dissociation
- Analgesia
- Morpholine dissociative with ketamine-like NMDA affinity
- Disorientation
- Impaired coordination
- Nausea
Mechanism
It is presumed to antagonize the receptor like other arylcyclohexylamines, producing dissociation by dampening excitatory glutamate signaling. Swapping the usual piperidine ring for a morpholine ring is thought to reduce potency relative to 3-MeO-PCP, but affinity data in humans are scarce, so the mechanism is described conservatively.
receptor fingerprint
Antagonist
Safetyrisks and cautions, not medical advice
As a dissociative it impairs coordination and judgment and can cause disorientation, nausea, and a dissociative state at higher doses. Human data are almost nonexistent, so its potency and safety margin are unknown and dosing is guesswork. It is dangerous combined with other depressants such as alcohol, benzodiazepines, or opioids. Not medical advice.
Subjective profileweighing the evidence above
Strictly experimental. It has real NMDA affinity and rodent evidence of reinforcing, abuse-prone properties, but almost no human data, so the dose is guesswork and the margin is unknown. Especially dangerous stacked with alcohol, benzodiazepines or opioids.
Resources
This entry is here for reference.
Research
- 1.Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues
- 2.Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay
- 3.4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels.
3 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
How does it differ from 3-MeO-PCP?
The morpholine ring is thought to make it less potent, but it is far less studied, so its effects are less predictable.
Is there human data?
Very little. It is a highly obscure analog, so its risks and dosing are essentially uncharacterized.
What are the main risks?
The usual dissociative impairments plus the uncertainty of an under-studied compound and additive sedation with other depressants.
Adverse effects
- Disorientation
- Impaired coordination
- Nausea
Notes and cautions
- Unknown potency and margin